These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 10024503)

  • 1. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
    Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
    Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperlipidaemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoprotein C1.
    Koopmans SJ; Jong MC; Que I; Dahlmans VE; Pijl H; Radder JK; Frölich M; Havekes LM
    Diabetologia; 2001 Apr; 44(4):437-43. PubMed ID: 11357474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice.
    Zsigmond E; Kobayashi K; Tzung KW; Li L; Fuke Y; Chan L
    Hum Gene Ther; 1997 Nov; 8(16):1921-33. PubMed ID: 9382958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice.
    van der Hoogt CC; Berbée JF; Espirito Santo SM; Gerritsen G; Krom YD; van der Zee A; Havekes LM; van Dijk KW; Rensen PC
    Biochim Biophys Acta; 2006 Feb; 1761(2):213-20. PubMed ID: 16478678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia.
    Nomura S; Merched A; Nour E; Dieker C; Oka K; Chan L
    Gene Ther; 2004 Oct; 11(20):1540-8. PubMed ID: 15269711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
    Jong MC; Havekes LM
    Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opposing effects of apolipoprotein m on catabolism of apolipoprotein B-containing lipoproteins and atherosclerosis.
    Christoffersen C; Pedersen TX; Gordts PL; Roebroek AJ; Dahlbäck B; Nielsen LB
    Circ Res; 2010 May; 106(10):1624-34. PubMed ID: 20360257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term reversal of hypercholesterolemia in low density lipoprotein receptor (LDLR)-deficient mice by adenovirus-mediated LDLR gene transfer combined with CD154 blockade.
    Stein CS; Martins I; Davidson BL
    J Gene Med; 2000; 2(1):41-51. PubMed ID: 10765504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of apolipoprotein E isoforms on lipolysis of very low-density lipoprotein triglycerides.
    Hara M; Iso-O N; Satoh H; Noto H; Togo M; Ishibashi S; Kimura S; Kadowaki T; Hashimoto Y; Tsukamoto K
    Metabolism; 2006 Aug; 55(8):1129-34. PubMed ID: 16839851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor.
    Kobayashi K; Oka K; Forte T; Ishida B; Teng B; Ishimura-Oka K; Nakamuta M; Chan L
    J Biol Chem; 1996 Mar; 271(12):6852-60. PubMed ID: 8636110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice.
    Bovenschen N; van Dijk KW; Havekes LM; Mertens K; van Vlijmen BJ
    Br J Haematol; 2004 Sep; 126(5):722-5. PubMed ID: 15327526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.
    Tacken PJ; Beer FD; Vark LC; Havekes LM; Hofker MH; Willems Van Dijk K
    Biochem J; 2000 Apr; 347(Pt 2):357-61. PubMed ID: 10749663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII.
    Ananyeva NM; Makogonenko YM; Kouiavskaia DV; Ruiz J; Limburg V; Meijer AB; Khrenov AV; Shima M; Strickland DK; Saenko EL
    Blood Coagul Fibrinolysis; 2008 Mar; 19(2):166-77. PubMed ID: 18277139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-module region of the low-density lipoprotein receptor sufficient for formation of complexes with apolipoprotein E ligands.
    Fisher C; Abdul-Aziz D; Blacklow SC
    Biochemistry; 2004 Feb; 43(4):1037-44. PubMed ID: 14744149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia.
    Belalcazar LM; Merched A; Carr B; Oka K; Chen KH; Pastore L; Beaudet A; Chan L
    Circulation; 2003 Jun; 107(21):2726-32. PubMed ID: 12742997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice.
    Jong MC; van Ree JH; Dahlmans VE; Frants RR; Hofker MH; Havekes LM
    Biochem J; 1997 Jan; 321 ( Pt 2)(Pt 2):445-50. PubMed ID: 9020879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van 't Hof HB; Mol MJ; van der Boom H; van der Zee A; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1996 Mar; 97(5):1184-92. PubMed ID: 8636429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity causes very low density lipoprotein clearance defects in low-density lipoprotein receptor-deficient mice.
    Coenen KR; Gruen ML; Hasty AH
    J Nutr Biochem; 2007 Nov; 18(11):727-35. PubMed ID: 17418556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.